[go: up one dir, main page]

MX2016015907A - Metodos y composiciones para tratar desordenes por deficiencia de oxido nitrico y condiciones relacionadas. - Google Patents

Metodos y composiciones para tratar desordenes por deficiencia de oxido nitrico y condiciones relacionadas.

Info

Publication number
MX2016015907A
MX2016015907A MX2016015907A MX2016015907A MX2016015907A MX 2016015907 A MX2016015907 A MX 2016015907A MX 2016015907 A MX2016015907 A MX 2016015907A MX 2016015907 A MX2016015907 A MX 2016015907A MX 2016015907 A MX2016015907 A MX 2016015907A
Authority
MX
Mexico
Prior art keywords
compositions
methods
nitric oxide
related conditions
deficiency disorders
Prior art date
Application number
MX2016015907A
Other languages
English (en)
Inventor
J Lefer David
Giordano Anthony
Original Assignee
Sulfagenix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sulfagenix Inc filed Critical Sulfagenix Inc
Publication of MX2016015907A publication Critical patent/MX2016015907A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención presenta métodos y composiciones para reducir los niveles de proteína reactiva C (CRP), IL-6, y/o IFN-? en suero en un paciente en necesidad de ello, y para tratar enfermedades y condiciones asociadas con niveles de CRP, IL-6, y/o IFN-? en suero incrementados. La invención también presenta métodos y composiciones para tratar a un paciente diagnosticado con, o en riesgo de desarrollar, enfermedad periodontal mediante administrar un corticoesteroide o un análogo del mismo y/o una pirimidopirimidina tetra-sustituida o un regulador hacia arriba de análogo de adenosina.
MX2016015907A 2014-06-03 2015-06-02 Metodos y composiciones para tratar desordenes por deficiencia de oxido nitrico y condiciones relacionadas. MX2016015907A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462007100P 2014-06-03 2014-06-03
PCT/US2015/033712 WO2015187649A1 (en) 2014-06-03 2015-06-02 Methods and compositions for treating nitric oxide deficiency disorders and related conditions

Publications (1)

Publication Number Publication Date
MX2016015907A true MX2016015907A (es) 2018-08-01

Family

ID=54767267

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016015907A MX2016015907A (es) 2014-06-03 2015-06-02 Metodos y composiciones para tratar desordenes por deficiencia de oxido nitrico y condiciones relacionadas.

Country Status (4)

Country Link
US (1) US20170087180A1 (es)
EP (1) EP3151671A4 (es)
MX (1) MX2016015907A (es)
WO (1) WO2015187649A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3331894B1 (en) 2015-08-05 2021-02-17 Metro International Biotech, LLC Nicotinamide mononucleotide derivatives and their uses
GB2542881B (en) 2015-10-02 2020-01-01 Carr Andrew Crystal forms of ß-nicotinamide mononucleotide
US10238685B2 (en) * 2015-12-02 2019-03-26 Johnson & Johnson Consumer Inc. Compositions containing polymeric sulfur and uses thereof
WO2018112541A1 (en) * 2016-12-21 2018-06-28 Newsouth Innovations Pty Limited Methods for enhancing vascular density
CU20200106A7 (es) 2018-06-20 2021-08-06 Axcella Health Inc Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias
WO2021011808A1 (en) * 2019-07-17 2021-01-21 Cytokinetics, Inc. Cardiac sarcomere inhibitor oral formulations
DE102020002198A1 (de) 2020-04-07 2021-11-04 Christian Scharrer COVID - Medikament
US20220331353A1 (en) * 2021-02-25 2022-10-20 Calroy Health Sciences, Llc Synergistic compositions and methods to increase vascular nitric oxide to treat endothelial dysfunction and related conditions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL138686A0 (en) * 1999-10-01 2001-10-31 Pfizer Prod Inc α- SULFONYLAMINO HYDROXAMIC ACID INHIBITORS OF MATRIX METALLOPROTEINASES FOR THE TREATMENT OF PERIPHERAL OR CENTRAL NERVOUS SYSTEM DISORDERS
US7235237B2 (en) * 1999-10-29 2007-06-26 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
EP1753734A1 (en) * 2004-05-05 2007-02-21 Renopharm Ltd. Nitric oxide donors and uses thereof
WO2008060332A2 (en) * 2006-06-02 2008-05-22 The Trustees Of Columbia University In The City Of New York Methods for treating or reducing muscle fatigue
US20080026061A1 (en) * 2006-06-22 2008-01-31 Reichwein John F Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide
US20100143503A1 (en) * 2006-12-22 2010-06-10 Ikaria, Inc. Combinations of nitric oxide and sulfide and methods of use and manufacture thereof
WO2009059271A1 (en) * 2007-11-02 2009-05-07 University Of Miami Diagnosis and treatment of cardiac disorders
US8906693B2 (en) * 2009-06-03 2014-12-09 University Of Florida Research Foundation, Inc. Materials and methods for measuring nitric oxide levels in biological fluids
CN102078327B (zh) * 2009-11-27 2014-01-08 复旦大学 炔丙基半胱氨酸在制备治疗阿尔茨海默病药物中的用途
US20140112983A1 (en) * 2011-04-14 2014-04-24 Theravasc Inc. Nitrite compositions and uses thereof
MX360050B (es) * 2011-09-14 2018-10-19 Nuevas Alternativas Naturales S A P I De C V Preparacion y composiciones de azufre con valencia cero, altamente bio-disponibles, y sus usos.

Also Published As

Publication number Publication date
WO2015187649A1 (en) 2015-12-10
EP3151671A1 (en) 2017-04-12
US20170087180A1 (en) 2017-03-30
EP3151671A4 (en) 2018-03-07

Similar Documents

Publication Publication Date Title
MX2016015907A (es) Metodos y composiciones para tratar desordenes por deficiencia de oxido nitrico y condiciones relacionadas.
MY197345A (en) Antibody molecules to april and uses thereof
PL3298140T3 (pl) Kompozycje do leczenia patologicznych stanów zwapnienia i sposoby ich stosowania
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
NZ720769A (en) Anti-siglec-8 antibodies and methods of use thereof
MX389228B (es) Composiciones para tratar el cabello.
MX2022001043A (es) Moleculas de anticuerpo que se unen a lag-3 y usos de las mismas.
BR112018010089A2 (pt) composições compreendendo cepas bacterianas
WO2014164704A3 (en) Compounds and compositions for the treatment of cancer
ZA201600453B (en) Compositions, methods and kits for diagnosing and treating cd206 expressing cell-related disorders
HK1220980A1 (zh) 用於治疗庞贝氏症的方法和组合物
WO2013177187A3 (en) Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
WO2014165090A8 (en) Compounds for the treatment of tuberculosis
MX2015017253A (es) Composiciones y metodos para tratar trastornos metabolicos.
SG11201705450SA (en) Bacteria-comprising compositions and methods of using the same for treating and/or preventing gastrointestinal, metabolic and/or other diseases
IL241823B (en) Preparations containing novyi .c and their uses for the treatment of cancerous tumors
HK1245158A1 (zh) 阿吡莫德组合物及其使用方法
WO2014205266A3 (en) Compositions and methods for detecting and treating glioblastoma
MX2017006026A (es) Apilimod para uso en el tratamiento de cancer colorrectal.
PH12017501864A1 (en) Compositions and methods for treating autism
EP3186269A4 (en) Compositions, methods and kits for treating complement related disorders
WO2015168602A3 (en) Methods and compositions for the diagnosis and treatment of kawasaki disease
IL251881A0 (en) Preparations for the treatment of acute, post-operative or chronic pain and methods of using them